← Back to patent-cliff list
VP-001
Tier C — Watch / tradeVP-001
PYC Therapeutics LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：PRPF31
Indications (approved)：Retinitis pigmentosa, 视网膜变性, 视网膜病变, 视网膜营养性萎缩, 遗传性眼睛疾病, 视网膜发育不良, Ophthalmic disease
Regional status
US
Phase II
2025-06-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of VP-001?
Approved indications include: Retinitis pigmentosa, 视网膜变性, 视网膜病变, 视网膜营养性萎缩, 遗传性眼睛疾病, 视网膜发育不良, Ophthalmic disease.
When does the VP-001 patent expire?
No public expiry year is available for VP-001 yet; this page updates once verified.
How do I get a quote for VP-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30